{"slug":"kyowa-hakko-kirin","name":"교와기린","name_en":"Kyowa Hakko Kirin","ticker":"4151.T","updated_at":"2026-07-11T10:21:02.374+00:00","canonical":"https://valuechain.wiki/kyowa-hakko-kirin","kicker":"닛케이 225","kicker_en":"Nikkei 225","lead":"항체 신약에 강점을 가진 기린 계열의 일본 제약사다. 닛케이 225 구성종목. 밸류체인 관계·수치 데이터는 조사 전인 기본 노드로, AI 질문 수요가 관측되면 상세 노드로 승격된다.","lead_en":"Kyowa Kirin is a Kirin-affiliated Japanese drugmaker strong in antibody therapeutics. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.","segments":{"parts":[{"name":"신장 질환 치료제"},{"name":"항암제"},{"name":"면역·알레르기"}],"total":"약 ¥4,400억 (FY2024)"},"segments_en":{"parts":[{"name":"Nephrology"},{"name":"Oncology"},{"name":"Immunology and allergy"}],"total":"~¥440B (FY2024)"},"returns_yearly":{"2021":-6.7,"2022":2.9,"2023":-17.4,"2024":1.7,"2025":10.7,"2026":6.9},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":null,"analysis_en":null,"analysis_asof":null},"edges":[]}